Medtech bleeds corporate venture cash
Overall venture investment in the sector remains steady, but the big strategics back off.
Ember burns bright for Angle
A clinical hit could allow the group’s liquid biopsy to expand from breast cancer to ovarian.
Esmo 2022 – Galleri’s real-world exhibition disappoints
Grail finds the path for its liquid biopsy less clear than it might have hoped.
Delfi aims for a cheaper liquid biopsy
With a fresh $225m in the bank, Delfi works towards a cut-price, next-generation lung cancer screen.